Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NAPROSYN vs EC-NAPROSYN
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain,Fever
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
500-1000 mg orally twice daily; maximum 1500 mg/day.
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Extensively metabolized in the liver via glucuronidation and oxidation; CYP450 involvement is minor. Major metabolite is 6-desmethylnaproxen.
GFR 30-59 m L/min: decrease dose by 50% or use alternative; GFR <30 m L/min: contraindicated.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation, which can be fatal.
First trimester: Case-control studies suggest a small increased risk of cardiac defects and oral clefts; absolute risk remains low. Second/third trimester: Exposure may cause premature constriction of the ductus arteriosus, oligohydramnios due to fetal renal effects, and risk of necrotizing enterocolitis, intracranial hemorrhage, and renal dysfunction in the neonate; avoid after 30 weeks gestation.
First trimester: Risk of cardiac malformations and gastroschisis; avoid use. Second trimester: Use only if clearly needed; may cause oligohydramnios. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus and persistent pulmonary hypertension in the neonate.
Naprosyn (naproxen) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~12-17 hours), allowing twice-daily dosing. Use with caution in patients with cardiovascular disease, renal impairment, or history of GI bleeding. It can mask signs of infection. Monitor renal function and blood pressure regularly. Avoid concurrent use with other NSAIDs or anticoagulants due to increased bleeding risk. Naprosyn may cause photosensitivity; advise sun protection.
EC-NAPROSYN is an enteric-coated formulation of naproxen designed to reduce gastric irritation. Onset of action is delayed due to enteric coating; not suitable for acute pain where rapid absorption is needed. Do not crush or chew tablets. Monitor renal function in elderly and patients with creatinine clearance <30 m L/min. Avoid concurrent use of other NSAIDs, including OTC naproxen. Use lowest effective dose for shortest duration. Significant drug interaction with methotrexate, lithium, and anticoagulants.
No interactions on record
No interactions on record
NAPROSYN and EC-NAPROSYN are distinct pharmacological agents. NAPROSYN belongs to the NSAID class and is primarily used for Rheumatoid arthritisOsteoarthritisAnkylosing spondylitisJuvenile arthritisTendonitisBursitisAcute goutPrimary dysmenorrheaMild to moderate pain. EC-NAPROSYN belongs to the NSAID class and is primarily used for Rheumatoid arthritisOsteoarthritisAnkylosing spondylitisJuvenile arthritisTendonitisBursitisAcute goutPrimary dysmenorrheaMild to moderate painFever. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. NAPROSYN carries a safety status of Category C, whereas EC-NAPROSYN safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Naproxen is extensively metabolized in the liver via cytochrome P450 (CYP) enzymes, primarily CYP2C9, to 6-O-desmethyl naproxen, and undergoes glucuronidation.
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
>99% bound to albumin.
>99.7% bound, primarily to albumin
0.16 L/kg (approximately 10-12 L in a 70 kg adult). Low Vd indicates distribution primarily in plasma and extracellular fluid.
0.16-0.2 L/kg (low, consistent with extensive plasma protein binding)
Oral: 95% (completely absorbed). Rectal: approximately 80% of oral bioavailability.
Oral: 95% (enteric-coated formulation similar to immediate-release)
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated.
For juvenile arthritis: 10-15 mg/kg/day divided twice daily; maximum 1000 mg/day. For other indications: 5-10 mg/kg/dose every 8-12 hours.
≥2 years: 10-20 mg/kg orally twice daily; maximum 1000 mg/day.
Start at lowest effective dose (250 mg twice daily); monitor renal function and gastrointestinal bleeding risk.
Start at lowest effective dose; maximum 1000 mg/day due to increased risk of GI and renal adverse effects.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Naproxen is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Naproxen may be taken with food or milk to minimize gastrointestinal irritation. Avoid alcohol, as it increases the risk of stomach bleeding. No specific food restrictions beyond general NSAID precautions.
Avoid alcohol; may increase risk of GI bleeding. Take with food or milk to minimize GI irritation. Avoid high-potassium foods if renal impairment is a concern (concurrent ACE inhibitors/ARBs). No other specific food restrictions.
Naproxen is excreted into breast milk in small amounts (M/P ratio approximately 0.01). The relative infant dose is about 1% of the maternal weight-adjusted dose. Use with caution in breastfeeding; monitor infant for gastrointestinal effects, rash, or bleeding.
Naproxen is excreted in breast milk in small amounts (M/P ratio approximately 0.01). Use with caution, especially in infants with compromised renal function or bleeding risk. Short-term use is likely compatible; avoid prolonged use.
Due to increased renal clearance and volume of distribution in pregnancy, standard doses may be subtherapeutic; however, increased doses are not recommended due to fetal risks. Use lowest effective dose for shortest duration; avoid in third trimester.
No specific dose adjustment recommended, but use lowest effective dose for shortest duration. Due to increased volume of distribution and renal clearance in pregnancy, standard doses may be less effective; adjust based on clinical response.
Take with food or milk to reduce stomach upset.,Do not take more than the recommended dose; overdose can cause serious side effects.,Avoid alcohol while taking this medication to lower the risk of stomach bleeding.,Tell your doctor if you have a history of stomach ulcers, high blood pressure, or kidney disease.,Watch for signs of stomach bleeding: black/tarry stools, vomit that looks like coffee grounds.,Stop taking and seek medical help if you experience chest pain, weakness, slurred speech, or shortness of breath.,Store at room temperature away from moisture and heat.,Do not combine with other products containing naproxen or other NSAIDs.
Take with food or milk to reduce stomach upset.,Swallow tablet whole; do not crush, chew, or break.,Avoid alcohol while taking this medication.,Do not take with other NSAIDs or aspirin.,Contact your doctor if you experience black/tarry stools, vomiting blood, or severe abdominal pain.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Stay hydrated; report swelling or weight gain.,Do not take within 2 hours of antacids.